Stephen R Broderick1, Aalok P Patel2, Traves D Crabtree2, Jennifer M Bell2, Daniel Morgansztern3, Clifford G Robinson4, Daniel Kreisel2, A Sasha Krupnick2, G Alexander Patterson2, Bryan F Meyers2, Varun Puri5. 1. Department of Surgery, Division of Cardiothoracic Surgery, St. Luke's Hospital, Chesterfield, Missouri. 2. Department of Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri. 3. Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. 5. Department of Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri. Electronic address: puriv@wudosis.wustl.edu.
Abstract
BACKGROUND: The role of pneumonectomy after neoadjuvant therapy for stage IIIA non-small cell lung cancer (NSCLC) remains uncertain. METHODS: Patients who underwent pneumonectomy for clinical stage IIIA NSCLC were abstracted from the National Cancer Database. Individuals treated with neoadjuvant therapy, followed by resection, were compared with those who underwent resection, followed by adjuvant therapy. Logistic regression was performed to identify factors associated with 30-day mortality. A Cox proportional hazards model was fitted to identify factors associated with survival. RESULTS: Pneumonectomy for stage IIIA NSCLC with R0 resection was performed in 1,033 patients; of these, 739 (71%) received neoadjuvant therapy, and 294 (29%) underwent resection, followed by adjuvant therapy. The two groups were well matched for age, gender, race, income, Charlson comorbidity score, and tumor size. The 30-day mortality rate in the neoadjuvant group was 7.8% (57 of 739). Median survival was similar between the two groups: 25.9 months neoadjuvant vs 31.3 months adjuvant (p = 0.74). A multivariable logistic regression model for 30-day mortality demonstrated that increasing age, annual income of less than $35,000, nonacademic facility, and right-sided resection were associated with an elevated risk of 30-day mortality. A multivariable Cox model for survival demonstrated that increasing age was predictive of shorter survival and that administration of neoadjuvant therapy did not confer a survival advantage over adjuvant therapy (p = 0.59). CONCLUSIONS: Most patients who require pneumonectomy for clinical stage IIIA NSCLC receive neoadjuvant chemoradiotherapy, without an improvement in survival. In these patients, primary resection, followed by adjuvant chemoradiotherapy, may provide equivalent long-term outcomes.
BACKGROUND: The role of pneumonectomy after neoadjuvant therapy for stage IIIA non-small cell lung cancer (NSCLC) remains uncertain. METHODS:Patients who underwent pneumonectomy for clinical stage IIIA NSCLC were abstracted from the National Cancer Database. Individuals treated with neoadjuvant therapy, followed by resection, were compared with those who underwent resection, followed by adjuvant therapy. Logistic regression was performed to identify factors associated with 30-day mortality. A Cox proportional hazards model was fitted to identify factors associated with survival. RESULTS: Pneumonectomy for stage IIIA NSCLC with R0 resection was performed in 1,033 patients; of these, 739 (71%) received neoadjuvant therapy, and 294 (29%) underwent resection, followed by adjuvant therapy. The two groups were well matched for age, gender, race, income, Charlson comorbidity score, and tumor size. The 30-day mortality rate in the neoadjuvant group was 7.8% (57 of 739). Median survival was similar between the two groups: 25.9 months neoadjuvant vs 31.3 months adjuvant (p = 0.74). A multivariable logistic regression model for 30-day mortality demonstrated that increasing age, annual income of less than $35,000, nonacademic facility, and right-sided resection were associated with an elevated risk of 30-day mortality. A multivariable Cox model for survival demonstrated that increasing age was predictive of shorter survival and that administration of neoadjuvant therapy did not confer a survival advantage over adjuvant therapy (p = 0.59). CONCLUSIONS: Most patients who require pneumonectomy for clinical stage IIIA NSCLC receive neoadjuvant chemoradiotherapy, without an improvement in survival. In these patients, primary resection, followed by adjuvant chemoradiotherapy, may provide equivalent long-term outcomes.
Authors: Michael Thomas; Christian Rübe; Petra Hoffknecht; Hans N Macha; Lutz Freitag; Albert Linder; Norman Willich; Michael Hamm; Gerhard W Sybrecht; Dieter Ukena; Karl-Matthias Deppermann; Cornelia Dröge; Dorothea Riesenbeck; Achim Heinecke; Cristina Sauerland; Klaus Junker; Wolfgang E Berdel; Michael Semik Journal: Lancet Oncol Date: 2008-06-24 Impact factor: 41.316
Authors: Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone Journal: J Natl Cancer Inst Date: 2007-03-21 Impact factor: 13.506
Authors: Felix G Fernandez; Seth D Force; Allan Pickens; Patrick D Kilgo; Theresa Luu; Daniel L Miller Journal: Ann Thorac Surg Date: 2011-07 Impact factor: 4.330
Authors: Daniel J Boffa; Jacquelyn G Hancock; Xiaopan Yao; Sarah Goldberg; Joshua E Rosen; Anthony W Kim; Amy Moreno; Frank C Detterbeck Journal: Ann Thorac Surg Date: 2014-11-20 Impact factor: 4.330
Authors: Anthony W Kim; L Penfield Faber; William H Warren; Sanjib Basu; Sean C Wightman; James A Weber; Philip Bonomi; Michael J Liptay Journal: Ann Thorac Surg Date: 2009-09 Impact factor: 4.330
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Martin J Edelman; Mohan Suntharalingam; Whitney Burrows; King F Kwong; Neha Mitra; Ziv Gamliel; Michelle Riley; Lindsay B Cooper; Nancy L Kennedy; Susan Buskirk; Petr Hausner; L Austin Doyle; Mark J Krasna Journal: Ann Thorac Surg Date: 2008-09 Impact factor: 4.330
Authors: K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: Godehard Friedel; Wilfried Budach; Juergen Dippon; Werner Spengler; Susanne Martina Eschmann; Christina Pfannenberg; Fawaz Al-Kamash; Thorsten Walles; Hermann Aebert; Thomas Kyriss; Stefanie Veit; Martin Kimmich; Michael Bamberg; Martin Kohlhaeufl; Volker Steger; Thomas Hehr Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Brendan T Heiden; Daniel B Eaton; Su-Hsin Chang; Yan Yan; Martin W Schoen; Li-Shiun Chen; Nina Smock; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri Journal: Chest Date: 2021-12-14 Impact factor: 10.262
Authors: Brendan T Heiden; Daniel B Eaton; Su-Hsin Chang; Yan Yan; Martin W Schoen; Li-Shiun Chen; Nina Smock; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri Journal: Ann Surg Date: 2021-11-18 Impact factor: 13.787
Authors: Liwen Xiong; Yuqing Lou; Hao Bai; Rong Li; Jinjing Xia; Wentao Fang; Jie Zhang; Han Han-Zhang; Analyn Lizaso; Bing Li; Aiqin Gu; Baohui Han Journal: J Int Med Res Date: 2019-12-29 Impact factor: 1.671